{"id":"e901e51a-4eaa-495c-bf3a-29f0352001ff","arxiv_id":"2501.15489","paper_version":1,"verdict":"CONDITIONAL","confidence":"MODERATE","novelty_score":1.0,"correctness_risk":"medium","formal_verification":"none","parameter_count":0,"one_line_summary":"A narrative review compiling AI and deep learning applications across ten cancer types and claiming improved diagnosis and treatment, without new experimental evidence.","lead":"This paper reviews existing research on AI and machine learning in oncology across ten cancer types. It argues that AI improves cancer detection and treatment, but it presents no new data or experiments.","discovery_kind":"review","skeptic_critique":{"model":"deepseek-v4-flash","headline":"The review's central claim rests on faithful transcription of cited studies, but Section 1.1 contains an internally impossible MammoScreen AUC/CI pair, so the evidence base is not currently trustworthy.","rationale":"The reader's CONDITIONAL verdict is appropriate. My stress-test found no reason to reject the broad claim that AI has potential in oncology, which is independently supported by the wider literature. However, the paper's specific evidentiary synthesis is not dependable because of a clear internal inconsistency in Section 1.1: a point estimate of 0.7494 cannot fall outside its own 95% CI of 0.754-0.840. Since the review's contribution is aggregation and narration of cited results, such an error directly undermines the reliability of that aggregation. I agree with the reader's weakest assumption that the accuracy and comparability of the cited performance metrics are load-bearing. The recommended check is minimal and could be automated across the tables. If the check resolves favorably, the conditional verdict can be strengthened; if it fails, the review needs major corrections before its synthesis is cited. Therefore the reader's verdict remains unchanged.","tokens_in":43550,"tokens_out":3053,"duration_ms":30321,"concrete_test":"Retrieve the original MammoScreen study (reference [30]) and verify the exact reported AUC and 95% CI. If the source does not contain AUC = 0.7494 with CI [0.754, 0.840], Section 1.1 is demonstrably misreported, and the paper's evidence base requires a full audit of every table's metrics against their cited sources before the central claim can be accepted.","verdict_should_be":"UNCHANGED","load_bearing_attack":"Section 1.1 reports MammoScreen AUC = 0.7494 with 95% CI 0.754-0.840. A 95% confidence interval must contain the point estimate; here the lower bound (0.754) is above the reported AUC (0.7494), so at least one of these numbers is wrong. This is not cosmetic: the paragraph uses the result to argue that adding AI to radiologists improves screening accuracy. If the AUC or the CI is misreported, the specific evidence as presented is invalid. Similar anomalies appear elsewhere, e.g., Table 4 gives sensitivity as '90 to 47%' and specificity as '84 to 84%', which are presumably 90.47% and 84.84% but are not rendered correctly. Since this is a review, its central claim that AI improves detection across multiple cancer types depends on accurate, context-preserving transcription of cited metrics. One verified internal inconsistency raises the risk that other tables inherit uncaught transcription errors, so the review's synthesis and its abstract-level claim cannot be relied on until the numbers are checked against primary sources.","agreement_with_reader":"agree"},"referee_report":{"model":"deepseek-v4-flash","summary":"This manuscript is a narrative review of artificial intelligence (AI), machine learning (ML), and deep learning (DL) applications in oncology, covering lung, breast, colorectal, liver, gastric, esophageal, cervical, thyroid, prostate, and skin cancers. For each cancer type it summarizes conventional diagnostic methods, their limitations, and recent AI-based approaches, with performance metrics compiled into tables. The paper argues that AI can improve early detection, diagnostic accuracy, and personalized treatment planning, and it concludes that AI is poised to transform oncology while acknowledging challenges such as data quality, algorithm bias, and regulatory/ethical concerns. The review contains no original models or derivations; its evidentiary value depends entirely on faithful transcription of the cited primary studies.","tokens_in":43883,"tokens_out":6149,"duration_ms":60665,"significance":"If the transcribed performance figures are accurate, the review would be a useful, broad reference snapshot of the AI-in-oncology literature, and it would support a measured conclusion that AI-assisted tools can augment diagnostic workflows across multiple cancer types. The manuscript also has strengths: it covers a wide range of cancer types in a structured way, includes many tables of cited studies and performance metrics, and explicitly flags clinically important caveats such as the lack of training data for darker skin tones, the heterogeneity of datasets, and the need for interpretability and clinical validation. However, the synthesis is only as reliable as its source transcription, and several verified internal inconsistencies currently undermine confidence in the numerical evidence base. Because the paper is a review, these errors are correctable, but they must be addressed before the central claim can be accepted.","major_comments":[{"comment":"The reported MammoScreen AUC of 0.7494 with a 95% CI of 0.754 to 0.840 is internally impossible, since the lower bound of a confidence interval must be below the point estimate. This is not cosmetic: the paragraph uses this result to claim that adding AI improves breast cancer screening accuracy, yet the printed numbers actually make the AI-assisted AUC appear lower than the unassisted AUC of 0.769 (0.724–0.814). Please recheck the values against reference [30] and correct the point estimate or the confidence interval, and audit the other figures in the same paragraph (false-positive and false-negative reductions) for consistency with the source.","section":"Section 1.1"},{"comment":"In the Fuzzy C-Means (FCM) row, the performance is printed as “Sn value is 90 to 47% Sp value is 84 to 84%”, which is not a valid reporting of sensitivity and specificity. The body text in Section 3.1 states the correct values as 90.47% and 84.84%, so the table entry appears to be a garbled transcription. As printed, the table cannot support the claim that FCM achieved 87% accuracy with these sensitivity and specificity values. Please correct the table formatting and verify the underlying numbers against reference [167].","section":"Table 4"},{"comment":"Beyond the two errors above, several tables contain entries that appear to be out of place, malformed, or anachronistic. In Table 10, the “Function” entries for “Exosomal miRNAs in Liver Injury” and “Bibliometric Analysis on AI in Liver Cancer” appear to be swapped with the neighboring rows. In Table 12, the entry “MICCAI 2027 LITS database” is presumably “MICCAI 2017 LiTS database,” and Table 26 contains many rows with missing or blank performance cells and at least one “VGG-16” row with “-” as the dataset. Since the review’s conclusions rest on the accuracy of the cited metric tables, please perform a systematic source-verification pass rather than fixing only the isolated typos.","section":"Tables 10, 12, and 26"},{"comment":"The abstract and conclusion state that AI leads to “substantial improvements in patient outcomes,” but the cited evidence in this review is predominantly surrogate metrics such as AUC, sensitivity, and specificity. The breast cancer section (Section 3.1) itself acknowledges a lack of randomized controlled studies directly comparing AI as an independent screening system with radiologist interpretation, and the one screening example in Section 1.1 contains the internal inconsistency noted above. Please temper the conclusion to say that AI has shown promising improvements in diagnostic accuracy in retrospective and prospective cohorts, and explicitly note that direct evidence of improved patient-level outcomes remains limited.","section":"Abstract and Section 13"}],"minor_comments":[{"comment":"Figure 11 is captioned “Artificial Intelligence Workflow in Prostate Cancer Diagnosis and Management” but appears in the cervical cancer section and is referenced there; please either replace the figure with a cervical-cancer-specific diagram or move it to the prostate cancer section with matching text.","section":"Section 8.4 and Figure 11"},{"comment":"Figure 13 is referenced twice: once for prostate cancer in Section 10.3 and once for skin cancer in Section 11. The skin-cancer reference should be to Figure 14, since Figure 13 depicts prostate cancer. Please renumber or re-reference the figures consistently.","section":"Section 10.3 and Section 11"},{"comment":"The text in Section 5.3.1 refers to “colon cancer spreading to the liver” in a liver cancer section; this should be “colorectal cancer” for precision. Similarly, Table 12’s “MICCAI 2027” should be corrected to the actual year of the dataset challenge.","section":"Section 5.3.1 and Table 12"},{"comment":"The manuscript contains numerous typos and inconsistent formatting, examples including “color ectal cancer” (Section 4), “faces” for “feces” (Section 4.1), “Al” for “AI” (Table 1 caption area), and “a motel YOLO3” (Table 28). A careful copyedit is needed throughout.","section":"General"},{"comment":"The paragraph after the MammoScreen discussion reports US/UK false-positive and false-negative reductions and cites reference [29], but the preceding sentence about “500 randomly selected cases” appears to describe a different study; please make the narrative attribution to specific sources explicit for each set of numbers.","section":"Section 1.1"}],"recommendation":"major_revision","confidential_remarks":"The paper is a broad narrative review with no original methods, and its value depends on the fidelity of its transcription of primary sources. The internally impossible MammoScreen AUC/CI pair in Section 1.1 is a confirmed, load-bearing error, and the garbled entries in Tables 4, 10, 12, and 26 suggest a more widespread reliability problem. I see no evidence of misconduct, but the authors should be asked to audit every performance metric against the cited studies and to provide a table of corrections before the manuscript can be considered reliable. Given the breadth and the number of presentation issues, this is better suited to a review-oriented venue, and the current version is not suitable for publication as a reference review until the source-verification pass is completed."},"author_rebuttal":null,"desk_editor":{"model":"deepseek-v4-flash","letter":"Colleague,\n\nThis is a narrative review of AI in oncology spanning ten cancer types. There is no new data, no method, no framework; the contribution is a themed list of citations and tables of performance metrics. It does organize a lot of literature, and a newcomer could get a quick map of the field from the scope alone.\n\nBut the evidence base is not trustworthy as it stands. Section 1.1 reports MammoScreen AUC 0.7494 with a 95% CI of 0.754–0.840, which is internally impossible: the lower bound exceeds the point estimate. Table 4 gives sensitivity as \"90 to 47%\" instead of 90.47%. Figure 11's caption is about prostate cancer while the figure sits in the cervical cancer section. These are not cosmetic typos; they are warning signs that the transcription from primary sources is unreliable. This is a review, so faithful reporting is the entire value proposition.\n\nThere is also no stated methodology: no search strategy, no inclusion criteria, no critical appraisal. The paper aggregates numbers from heterogeneous datasets and designs and compares them as if they were apples to apples. That is a real limitation for a review aimed at clinicians.\n\nWhat is genuinely useful is the breadth. The tables compile many studies in one place, and if the numbers were verified against primary sources, the paper could serve as a reference list. The central claim—that AI improves detection across multiple cancer types—is consistent with the wider literature, so the conclusion is not wrong; it just is not adequately supported by the paper's own evidence.\n\nIf this crossed my desk, I would not send it to peer review in its current form. Any referee would trip over the MammoScreen CI in the first five minutes. I would send it back to the authors with a demand to re-check every metric against the primary sources, add a stated search and inclusion protocol, and replace the cheerleading with critical appraisal. If they fixed those things, it might deserve referee time as a review.\n\nOverall: a plausible takeaway and some organizing value, but currently too sloppy to cite or trust. You would get more from a well-conducted systematic review on any single cancer type.","headline":"A plausible, broad AI-in-oncology review undone by sloppy number transcription and no stated method; the conclusion is likely right, but the evidence as presented cannot be trusted.","tokens_in":44273,"tokens_out":2220,"would_cite":false,"duration_ms":23257,"reading_group":"maybe","serious_thinker":"unclear","would_accept_peer_review":false},"rs_alignment":null,"lean_confirmation":null,"pith_extraction":{"msc":[],"pacs":[],"model":"deepseek-v4-flash","headline":"The paper reviews evidence across ten cancer types and argues that machine-learning and deep-learning systems can match or exceed human diagnostic performance, improving early detection and enabling more personalized treatment.","keywords":["artificial intelligence","machine learning","deep learning","cancer diagnosis","medical imaging","oncology","computer-aided detection","precision medicine"],"falsifier":"A systematic audit of the reported metrics would settle it: for instance, the MammoScreen result in Section 1.1 reports an AUC of 0.7494 with a 95% confidence interval of 0.754–0.840, which is internally inconsistent because the point estimate lies outside its own interval; a re-run of the cited analyses, or a meta-analysis of prospective AI-assisted screening trials that failed to show improved sensitivity and specificity, would refute the review's central claim.","tokens_in":43369,"feed_emoji":"🧬","tokens_out":4597,"duration_ms":44282,"temperature":0.7,"pith_summary":"This paper is a review of artificial intelligence in oncology, covering ten major cancer types. It argues that machine-learning and deep-learning systems, applied to medical imaging, genomic sequencing, and pathology slides, can detect cancers earlier, improve diagnostic accuracy, cut false positives and negatives, and help tailor treatment per patient. The authors' claim matters because if the reported results transfer to clinical practice, AI could relieve specialist shortages, lower screening costs, and extend reliable cancer diagnostics to underserved regions. The review's case rests on the performance statistics of the cited studies, which it presents as evidence that AI now matches or exceeds human experts across many diagnostic tasks.","feed_headline":"AI matches expert doctors across 10 cancers, review finds","feed_subtitle":"Survey of imaging, genomics, and pathology studies says AI improves early detection and cuts false positives.","key_machinery":"The central object is the deep-learning pipeline over medical data, with convolutional neural networks (CNNs) as the workhorse for images from CT, MRI, ultrasound, endoscopy, and histopathology slides, and machine-learning classifiers for multi-omics data such as cfDNA, RNA-seq, DNA methylation, and copy-number profiles. Named architectures include ResNet, VGG, Inception, U-Net, Mask R-CNN, YOLO, and ensemble or CAD/CADe systems. These models carry the argument because each cited study's reported performance is the evidence the review marshals for AI's clinical value.","core_discovery":"On the paper's own terms, the central discovery is that AI-based diagnostic pipelines have reached a point where they consistently perform at or above the level of human specialists across a broad span of oncology tasks: detecting small lung nodules on CT, interpreting mammograms, classifying colorectal polyps during colonoscopy, diagnosing early esophageal and gastric cancers from endoscopic images, and grading prostate biopsies and skin lesions. The review documents this through tables of reported accuracy, AUC, sensitivity, and specificity values, and it argues that the pattern across ten cancers constitutes evidence for a general claim: AI can improve early detection, reduce diagnostic error, and support precision oncology.","pith_inferences":["A reasonable extension beyond the paper is that the biggest near-term impact of AI cancer detection may be in low-resource settings, where AI assistance could substitute for scarce specialists, provided the models are trained on representative local data.","The cross-cancer similarity in methods suggests that transfer learning and foundation models trained on data-rich cancers (lung, breast) could be adapted to rare cancers where large labeled datasets do not exist.","The internal inconsistency in the MammoScreen AUC and confidence interval in Section 1.1 hints that some transcribed performance numbers may be unreliable; standardizing how metrics are reported would strengthen the evidence base the review depends on.","The review's reliance on retrospective and single-center studies implies that the real test is prospective, multi-center validation under deployment conditions."],"forward_implications":["If the reported performance holds in prospective trials, AI-assisted screening can lower the number of false-positive and false-negative findings while easing the workload of radiologists and pathologists.","Multi-omics AI models can be used to identify cancer subtypes and predict which patients are more likely to respond to immunotherapy, enabling more personalized treatment decisions.","Real-time AI systems during endoscopy can raise adenoma detection rates and reduce missed lesions, which could lower colorectal cancer incidence.","AI tools that match expert readers may bring reliable cancer screening to regions that lack enough specialized clinicians.","The same imaging-plus-genomics pipeline applies across tumor types, so advances in one cancer can be adapted to others."],"supporting_citations":[{"why":"Supplies the MammoScreen breast-screening AUC comparison with and without AI, a headline quantitative example of AI benefit.","marker":"[30]"},{"why":"Supports the claim that computer-aided detection systems in colonoscopy improve adenoma detection rates.","marker":"[193]"},{"why":"Provides real-time AI diagnosis of esophageal cancer where the model surpasses non-specialist endoscopists.","marker":"[345]"},{"why":"Documents an AI system matching expert pathologist performance in detecting and grading prostate cancer on core biopsies.","marker":"[516]"},{"why":"Gives the cfDNA-based lung cancer detection result with AUC 0.98, supporting early detection through liquid biopsy.","marker":"[104]"},{"why":"Reports AI performance equal or superior to dermatologists in classifying skin lesions, a central example of expert-level accuracy.","marker":"[549]"}],"fun_headline_variants":["AI rivals specialists across 10 cancers, review shows","AI diagnostic power spans 10 cancers, review finds","Review: AI matches experts in cancer detection","AI enhances early cancer detection, review confirms","Ten cancers, one AI edge over standard diagnosis"],"cache_read_input_tokens":3200,"weakest_assumption_plain":"The review's conclusions rest on the assumption that the performance numbers reported in the cited studies are accurate, correctly transcribed, and comparable across datasets; if those numbers are wrong or taken out of context, the review's claims inherit the errors.","fun_headline_variants_meta":{"raw":{"variants":["AI rivals specialists across 10 cancers, review shows","AI diagnostic power spans 10 cancers, review finds","Review: AI matches experts in cancer detection","AI enhances early cancer detection, review confirms","Ten cancers, one AI edge over standard diagnosis"]},"model":"deepseek-v4-flash","effort":"low","cost_usd":0.000678,"raw_usage":{"total_tokens":3077,"prompt_tokens":935,"completion_tokens":2142,"prompt_tokens_details":{"cached_tokens":384},"prompt_cache_hit_tokens":384,"prompt_cache_miss_tokens":551,"completion_tokens_details":{"reasoning_tokens":2071}},"tokens_in":551,"tokens_out":2142,"duration_ms":14674,"temperature":1.0,"reasoning_tokens":2071,"cache_read_input_tokens":384,"cache_creation_input_tokens":0},"cache_creation_input_tokens":0},"created_at":"2026-08-10T14:13:46.261107+00:00","model_set":{"reader":"deepseek-v4-flash"},"falsifier":"A systematic audit of the reported metrics would settle it: for instance, the MammoScreen result in Section 1.1 reports an AUC of 0.7494 with a 95% confidence interval of 0.754–0.840, which is internally inconsistent because the point estimate lies outside its own interval; a re-run of the cited analyses, or a meta-analysis of prospective AI-assisted screening trials that failed to show improved sensitivity and specificity, would refute the review's central claim.","supporting_citations":[],"review_version":1}